Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Use of chlorprothixene and the risk of diabetes and major adverse cardiovascular events: A nationwide cohort study

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

DOI

  1. Short-term mortality following tramadol poisonings in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  2. COVID-19 clinical trials: Ethical and scientific consequences of the RECOVERY trial results

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  3. Active chlordiazepoxide metabolites in a patient needing life support after treatment of alcohol abstinence

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  4. Polypharmacy in schizophrenia

    Publikation: Bidrag til tidsskriftReviewpeer review

  1. Proinflammatory biomarkers are associated with prediabetes in patients with schizophrenia

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  2. SARS-CoV-2 seroprevalence among patients with severe mental illness: A cross-sectional study

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  3. FGF21 suppresses alcohol consumption through an amygdalo-striatal circuit

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  4. The role of glucagon-like peptide 1 (GLP-1) in addictive disorders

    Publikation: Bidrag til tidsskriftReviewpeer review

Vis graf over relationer

Chlorprothixene is commonly used off-label in low doses for sedative-hypnotic purposes although it might carry a risk of cardiometabolic adverse events due to its pharmacodynamic profile. We investigated the risk of diabetes and major adverse cardiovascular events (MACE) with use of low-dose chlorprothixene, compared with use of low-dose quetiapine in a nationwide cohort study, including all new users of low-dose chlorprothixene (n = 81 328) and low-dose quetiapine (n = 91 163) in Denmark 2000-2017. Main outcomes were diabetes and MACE (myocardial infarction, stroke and death from cardiovascular causes). The association between cumulative dose of chlorprothixene and the outcomes was tested in a case-control analysis. Low-dose chlorprothixene use was associated with increased risk of diabetes (intention-to-treat [ITT]-hazard ratio [HR]: 1.16; 95% CI: 1.08-1.25), compared with low-dose quetiapine use. This association strengthened when follow-up was restricted to time on treatment (as-treated [AT]-HR: 1.34; 95% CI: 1.14-1.56). Low-dose chlorprothixene use was also associated with increased risk of MACE (ITT-HR: 1.12; 95% CI: 1.04-1.21) and stroke (ITT-HR: 1.21; 95% CI: 1.06-1.37) but not with myocardial infarction (ITT-HR: 1.11; 95% CI: 0.95-1.30) nor death from cardiovascular causes (ITT-HR: 1.07; 95% CI: 0.96-1.20). Cumulative dose of chlorprothixene ≥6000 mg was associated with increased risk of diabetes (OR: 1.15-1.63; test for trend: p < 0.001), whereas cumulative dose of chlorprothixene ≥1500 mg was associated with increased risk of MACE (OR: 1.10-1.85; test for trend: p < 0.001). In conclusion, low-dose chlorprothixene use is associated with increased risk of cardiometabolic adverse events compared with low-dose quetiapine use.

OriginalsprogEngelsk
TidsskriftBasic & clinical pharmacology & toxicology
Vol/bind130
Udgave nummer4
Sider (fra-til)501-512
Antal sider12
ISSN1742-7843
DOI
StatusUdgivet - apr. 2022

Bibliografisk note

© 2022 The Authors. Basic & Clinical Pharmacology & Toxicology published by John Wiley & Sons Ltd on behalf of Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).

ID: 76480510